Plain-English translation of NCT06710067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Researchers are testing whether a new urine-based test can detect and tell apart different digestive diseases—including colorectal cancer, bacterial overgrowth in the small intestine, Crohn's disease, and celiac disease. The study will use artificial intelligence to analyze urine samples and build disease-specific models. The goal is to create a simple, non-invasive way to diagnose these conditions.
Current methods for diagnosing digestive diseases often require invasive procedures like colonoscopies or endoscopies. This study aims to develop a simpler urine test that could make diagnosis faster, easier, and less uncomfortable for patients.
You likely qualify if…
You likely don't qualify if…
Participation is straightforward and requires only a single visit. You will provide one urine sample and share relevant medical information with the research team. The entire process is non-invasive and designed to take minimal time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Sponsor
Luventix, Inc.
Enrollment target
~1,250 participants
Started
October 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Catherine Fine, MS, CGC
Luventix, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.